alirocumab vs simvastatin
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of alirocumab and simvastatin. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Praluent
Zocor
Praluent is a medicine that can lower cholesterol. It can also lower the risk of heart problems like heart attack or stroke in some adults.
No summary available.
Praluent is used to lower LDL cholesterol (bad cholesterol). It is used along with diet and exercise in adults with high cholesterol. It is also used in adults and children 8 years and older who have a genetic condition that causes high cholesterol.
Information not available.
Praluent is a PCSK9 inhibitor. It works by blocking a protein in your body called PCSK9. Blocking this protein helps your body remove LDL cholesterol from your blood.
Information not available.
- • Injection site reactions (redness, itching, swelling, pain)
- • Flu
- • Muscle pain
- • Diarrhea
- • Headache
- • Upper respiratory tract infection
- • Muscle pain
- • Diarrhea
- Myalgia 1,655
- Product Dose Omission 1,364
- Injection Site Pain 1,278
- Muscle Spasms 1,162
- Arthralgia 1,053
- Fatigue 13,574
- Nausea 12,945
- Dyspnoea 12,431
- Diarrhoea 11,813
- Dizziness 10,971
Serious allergic reactions have happened with Praluent, sometimes requiring hospitalization. If you have signs of a serious allergic reaction, stop using Praluent and get medical help right away.
No specific warnings noted.
There is not enough information about Praluent use during pregnancy to know if it is safe. If you are pregnant or plan to become pregnant, talk to your doctor before using Praluent.
No pregnancy information available.
Also Compare, Nearby Drugs
Compare alirocumab with
Compare simvastatin with
How to Read This alirocumab vs simvastatin Comparison
alirocumab is classified in the PCSK9 Inhibitor drug class, while simvastatin sits within the HMG-CoA Reductase Inhibitor (Statin) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, alirocumab has 6,512 submissions while simvastatin has 61,734. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for alirocumab or simvastatin.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.